Member Info for fundraiser222

EVG well respected institutional investors in at 37p including AXA, approx 28% free float, patented multi use drug SFX-01 with multi billion dollar revenue potential, two phase two trials in later stages, half yearly report imminent, huge multibag potential here imo dyor 97p broker target and lots of research available from the company website and director interviews. All UK based

Very few shares available mms are short on stock imo as no sellers at this low level

https://www.***************************/interview-evgen-pharma-plc-grossly-undervalued-say-northland-capital-partners/412721344

Yes I agree and the half yearly report if positive could easily take it past the ipo price of 37p, hardly any sellers as 72% owned by institutional investors and a lot of the 28% free float are in at 37p ipo price imo hence why it rockets on any buying it hit 29p two weeks ago on no news before the pharma sector became hot! Now news is imminent and the sector is hot

This share has been under the radar for years but with the pharma sector now hotting up it will Imo get the attention it deserves as its potential is mind blowing and the science is outstanding and fully patented and in later stage phase 2 trials

Yes it will go crazy when the half yearly report lands giving a full trial and company update the first full update for 5 months! The sector is hot atm and Evgen is over 50% below its ipo price of 37p yet has Released nothing but good news since they listed, orphan drug designation in the USA, compassionate use program for breast cancer trial as first patient on the trial has had no disease progression after 6 months!!

Only approx 28% free float it shifts like a rocket under any buying pressure institutional investors hold most the stock here at 37p

Fully agree and a little research here unveils the huge multi billion dollar revenue potential with their drug SFX-01 having multiple potential uses in multiple disease areas, half yearly report imminent imo you only have to look at the share register and the institutional investors on board at 37p to see where this is heading imo dyor

EVG well respected institutional investors in at 37p including AXA, approx 28% free float, patented multi use drug SFX-01 with multi billion dollar revenue potential, two phase two trials in later stages, half yearly report imminent, huge multibag potential here imo dyor 97p broker target

It has been released in the first week of December the last two years and will be out first update on the trials for 5 months and at a key stage. Interim breast cancer trial readout should be given an approx readout date in the results and we may also get an update on the compassionate use program. If the trials are ahead of schedule or some positive news on the trials is released this will fly imo, it hit 29p on no news 2 weeks ago so what will it do when positive news arrives.... 16p is an absolute bargain imo so close to news

$6bn market revenue opportunity for the two current phase 2 trials with the SAS trial already been granted orphan drug designation. SFX-01 also has the opportunity to be used in Austism, MS, arthritis and lots of different cancers... so from a £12m mcap and broker target of 97p I cannot see a better share on aim for blue sky multibag potential for 2018. Short term catalysts with half yearly results due in next few weeks with full trial update imo Q1 breast cancer interim trial readout will multibag it alone if positive. A transformational few months ahead staggering potential that’s for sure With the breast cancer trial already granting a compassionate use program to the first patient dosed with SFX-01 who showed no disease progression after 6 months of using the drug..... good luck all an exciting few weeks and months ahead imo dyor the rise a few weeks ago was a nice warm up for the main event and shows how quickly this will move on news imo

It was just a simple case of a share that is completely under the radar been bought up and as it moves quickly on small volume the price rocketed and attracted the traders keen to make a quick day profit. It fell back imo because the traders go and chase rainbows elsewhere but they will be back as soon as news lands imo and if the interim breast cancer readout is planned for Early q1 we will Imo see an explosive reaction in the share price way above the high of 29p just a few weeks ago. Half yearly report due out any day now and that should push us back into the 25p zone imo and if the herd get hold of it it will go crazy as we have seen this share moves like a rocket due to its huge potential and tiny freefloat

Yes and I think any future placing will be taken up by our large institutional share holders such as axa, any placing will most likely be done after the interim breast cancer trial readout and I think we could get an approximate date set for that key readout in the half yearly report due any day now. Very much looking forward to the half yearly report as we only really get two full reports each year on how the trials are going and we are now at the business end. A good half yearly report will imo push this back towards 30p and I expect momentum to then maintain and build as we move towards the interim breast cancer trial readout. It may well be the case that the trials are ahead of schedule that really would put a rocket up the share price

Patience is definitely required it’s a long term one and full readout of the phase 2 trials is not for another 12 months. I think the main concern amongst investors and the reason for the sell off is that Evgen will require a placing very soon as they run out of cash around March time imo people will look at it again after the placing as placings never go down too well with the market unfortunately

They are very risky naz but got to take a risk to see a reward hence why I bought as many as I could at 15p and below Monday and Tuesday, it’s a long term hold for me for the full trials readout in late 2018 but pleased ppl have made money today patience is key with these types of stocks and with interims due in December things will be clear re the cash position and how much we need to raise to complete the trials etc great day here today

No news expected from the trials until 2018 but interim results due in December which should make the cash position clear and any placing can at least now be done at a higher share price, excellent rise 100% in two days is great going

Full trial readout is not until late 2018 and they will need to raise a few quid before spring 2018 to complete the trials, that’s the negatives, positives are clear to see after researching hence my large position at 16p average

Don’t ask for advice if your nervous follow your own advice as harsh as that sounds

I will take a look at bmn now and let you know

My 14p buys yesterday are looking rather good I must say